Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

335.53
+14.144.40%
Volume:78.33K
Turnover:25.60M
Market Cap:39.76B
PE:-201.83
High:339.00
Open:320.34
Low:312.22
Close:321.39
52wk High:355.30
52wk Low:170.99
Shares:118.51M
Float Shares:75.99M
Volume Ratio:2.44
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6624
EPS(LYR):-6.1240
ROE:-4.98%
ROA:-1.06%
PB:10.55
PE(LYR):-54.79

Loading ...

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday

MT Newswires Live
·
Aug 25

BeOne Medicines Says EU Approves New Brukinsa Tablet That Reduces Daily Pill Count

MT Newswires Live
·
Aug 21

CCB International Maintains Cautious Optimism on Chinese Pharmaceutical Stocks Despite High Valuations, Assigns "Outperform" Rating to BeiGene (06160)

Stock News
·
Aug 14

BEIGENE (06160) Grants Restricted Stock Units Involving Approximately 344 Million American Depositary Shares

Stock News
·
Aug 14

RBC Raises Price Target on BeOne Medicines to $364 From $349, Keeps Outperform Rating

MT Newswires Live
·
Aug 07

Beone Medicines : Leerink Partners Raises Target Price to $345 From $334

THOMSON REUTERS
·
Aug 07

Nomura Adjusts BeOne Medicines Price Target to $366.06 From $352.60, Maintains Buy Rating

MT Newswires Live
·
Aug 07

BeOne Medicines Q2 Adjusted Earnings, Revenue Rise; 2025 Revenue Guidance Increased

MT Newswires Live
·
Aug 06

BeOne Medicines AG expected to post earnings of 11 cents a share - Earnings Preview

Reuters
·
Aug 04

BeOne Medicines Gets European Priority Medicines Designation for BGB-16673

MT Newswires Live
·
Aug 01

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday

MT Newswires Live
·
Jul 28

BeOne Medicines's Lung Cancer Treatment Recommended for Approval by EMA Panel

MT Newswires Live
·
Jul 28

Nomura Adjusts BeOne Medicines Price Target to $352.60 From $347.02, Maintains Buy Rating

MT Newswires Live
·
Jul 18

BeOne Medicines Is Maintained at Overweight by JP Morgan

Dow Jones
·
Jul 18

BeOne Medicines Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 16

RBC Raises Price Target on BeOne Medicines to $349 From $311, Keeps Outperform Rating

MT Newswires Live
·
Jul 16

Press Release: BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

Dow Jones
·
Jul 16

BeOne Medicines Gets European Commission Approval for Nasopharyngeal Carcinoma Combination Treatment

MT Newswires Live
·
Jul 10

BeOne Medicines Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jun 28

BeOne Medicines Price Target Maintained With a $311.00/Share by RBC Capital

Dow Jones
·
Jun 27